View more in

Selpercatinib Effective in Treating NSCLC

onclive.com
 2021-06-05

Treatment with selpercatinib demonstrated consistent efficacy in patients with RET fusion-positive non-small cell lung cancer, regardless of prior treatments. Treatment with selpercatinib (Retevmo) demonstrated consistent efficacy in patients with RET fusion-positive non-small cell lung cancer (NSCLC), regardless of prior treatments, according to findings from the LIBRETTO-001 trial (NCT03157128) presented at the virtual 2021 ASCO Annual Meeting.

www.onclive.com

Comments / 0

Comments / 0